Table 3. Hemoglobin decline at week 4 of therapy and management of anemia stratified by ITPA deficiency.

	No ITPA Deficiency (n = 48)	Mild ITPA Deficiency (n = 12)	Moderate ITPA deficiency (n = 9)	p
Mean Δ Hb week 4 g/dL	3,85	3,07	1,67	<0,0001
RbvDR, n(%)	29 (60%)	7 (58%)	6 (67%)	1*
Erythropoietin use, n(%)	31 (65%)	7 (58%)	5 (56%)	0.6*
Transfusion, n(%)	13 (27%)	2 (17%)	3 (33%)	1*
Treatment discontinuation within week 12, n(%)	10 (21%)	1 (8%)	1 (11%)	0.3*
Discontinuation for severe anemia, n(%)	4 (8%)	1 (8%)	0 (0%)	1*

*No ITPA deficiency vs any ITPA deficiency.